A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

NCT06769295 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Non-Small Cell

Interventions

DRUG: AK112

Sponsor

Sichuan University